An adjuvant therapy drug for breast cancer, Nerlynx, that failed to receive reimbursement in its first attempt is reattempting reimbursement in Korea.

According to industry sources, Bixink Therapeutics plans to apply for insurance benefits for its oral HER2 inhibitor Nerlynx (neratinib) in the second half of this year.

The drug reached deliberations by the Cancer Disease Deliberation Committee in February, but the committee did not reimbursement standards for the drug.

Nerlynx, which was originally developed by the US-based Puma Biotechnology, was first approved FDA approval as an extended adjuvant treatment for early-stage HER2-positive breast cancer in July 2017. Its ind